Literature DB >> 3191158

Alterations of elastin and elastase-like activities in aortae of diabetic rats.

C Y Kwan1, R R Wang, J S Beazley, R M Lee.   

Abstract

The elastin content of the aortic muscle and the elastase-like activity of the extracts of aortic muscle were studied in spontaneously diabetic BB rats and in rats made diabetic by a single bolus i.v. injection of alloxan. In both modes of diabetes, the total alkaline-insoluble aortic elastin content was significantly reduced in diabetic rats compared to that in the corresponding control rats. This reduction in aortic elastin was also accompanied by a consistent increase in the elastase-like activities of the aortic extracts prepared from the same tissues. Such a reciprocal relationship between aortic elastin content and elastase-like activity has previously been reported in rats with malignant hypertension. Since the rats used in this study were not hypertensive, the altered elastin metabolism observed in this work is likely to be a manifestation of diabetic disease and may in part account for the vascular changes associated with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191158     DOI: 10.1016/0304-4165(88)90027-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats.

Authors:  Chris J Sullivan; Thomas H Teal; Ian P Luttrell; Khoa B Tran; Mette A Peters; Hunter Wessells
Journal:  Physiol Genomics       Date:  2005-08-23       Impact factor: 3.107

2.  Interactions of elastin and aorta with sugars in vitro and their effects on biochemical and physical properties.

Authors:  C P Winlove; K H Parker; N C Avery; A J Bailey
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

Review 3.  Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function.

Authors:  Brittany Law; Vennece Fowlkes; Jack G Goldsmith; Wayne Carver; Edie C Goldsmith
Journal:  Microsc Microanal       Date:  2012-01-05       Impact factor: 4.127

4.  Increase in GLUT1 in smooth muscle alters vascular contractility and increases inflammation in response to vascular injury.

Authors:  Neeta Adhikari; David L Basi; Marjorie Carlson; Ami Mariash; Zhigang Hong; Ute Lehman; Sureni Mullegama; Edward K Weir; Jennifer L Hall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-10-14       Impact factor: 8.311

5.  Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation.

Authors:  Neel R Sodha; Richard T Clements; Munir Boodhwani; Shu-Hua Xu; Roger J Laham; Cesario Bianchi; Frank W Sellke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-12       Impact factor: 4.733

Review 6.  Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies.

Authors:  Theodore Mazzone; Alan Chait; Jorge Plutzky
Journal:  Lancet       Date:  2008-05-24       Impact factor: 79.321

7.  Diabetes and arterial extracellular matrix changes in a porcine model of atherosclerosis.

Authors:  Thomas O McDonald; Ross G Gerrity; Christy Jen; Hao-Ji Chen; Kathleen Wark; Thomas N Wight; Alan Chait; Kevin D O'Brien
Journal:  J Histochem Cytochem       Date:  2007-07-24       Impact factor: 2.479

8.  Gelatinase B(MMP-9) an apoptotic factor in diabetic transgenic mice.

Authors:  T M Camp; S C Tyagi; R M Senior; M R Hayden; S C Tyagi
Journal:  Diabetologia       Date:  2003-08-20       Impact factor: 10.122

Review 9.  Elastin, arterial mechanics, and cardiovascular disease.

Authors:  Austin J Cocciolone; Jie Z Hawes; Marius C Staiculescu; Elizabeth O Johnson; Monzur Murshed; Jessica E Wagenseil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-04-06       Impact factor: 4.733

Review 10.  Role of nitric oxide in matrix remodeling in diabetes and heart failure.

Authors:  Suresh C Tyagi; Melvin R Hayden
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.